(Q54377204)

English

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.

scientific article published in July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

0 references

decompensated cirrhosis

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

1

0 references

Tawesak Tanwandee

5

object named as

Tawesak Tanwandee

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

author name string

Maria Raptopoulou-Gigi

2

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Hugo Cheinquer

3

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Shiv Kumar Sarin

4

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Nancy Leung

6

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Cheng-Yuan Peng

7

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Robert P Myers

8

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Robert S Brown

9

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Lennox Jeffers

10

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Naoky Tsai

11

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Jolanta Bialkowska

12

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Shijie Tang

13

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Suzanne Beebe

14

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

Elizabeth Cooney

15

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

language of work or name

0 references

publication date

1 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

54

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

1

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

91-100

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Management of hyperlactatemia: no need for routine lactate measurements

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

21 January 2018

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of adult patients with ascites due to cirrhosis: an update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

7 January 2021

based on heuristic

inferred from DOI database lookup

Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24361

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.24361

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21503940

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54377204&oldid=1741936958"